Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Public ClinicalTrials.gov record NCT02861573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Study identification
- NCT ID
- NCT02861573
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 1,200 participants
Conditions and interventions
Interventions
- Abiraterone acetate 1000 mg Drug
- Belzutifan 120mg Biological
- Carboplatin Drug
- Dexamethasone 8 mg Other
- Docetaxel 75 mg/m^2 Drug
- Enzalutamide 160 mg Drug
- Etoposide Drug
- Lenvatinib Drug
- Olaparib 300 mg Drug
- Olaparib 400 mg Drug
- Pembrolizumab 200 mg Biological
- Pembrolizumab/Vibostolimab coformulation Biological
- Prednisone 5 mg Drug
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2016
- Primary completion
- Oct 21, 2027
- Completion
- Jul 23, 2028
- Last update posted
- Feb 16, 2026
2016 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Call for Information (Investigational Site 2041) | Aurora | Colorado | 80045 | Recruiting |
| Call for Information (Investigational Site 2091) | Cleveland | Ohio | 44195 | Recruiting |
| Call for Information (Investigational Site 2094) | Portland | Oregon | 97239 | Recruiting |
| Call for Information (Investigational Site 0008) | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Call for Information (Investigational Site 0019) | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Call for Information (Investigational Site 2090) | Germantown | Tennessee | 38138 | Recruiting |
| Call for Information (Investigational Site 0016) | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02861573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02861573 live on ClinicalTrials.gov.